Bold claim: a five-minute HIV test can tell active infection from vaccine-induced antibodies, dramatically reducing false positives from vaccination alone. Researchers report a fast, accessible diagnostic that, in Science Advances, matches or surpasses existing methods in distinguishing people with active HIV infection from those who merely carry antibodies due to vaccination. The study notes that while no HIV vaccines are approved yet, several candidates are in clinical trials. Preventive vaccines aim to prompt the immune system to produce antibodies against HIV antigens—such as core proteins and envelope glycoproteins—which are often the same targets used by standard HIV tests. This overlap can produce vaccine-induced seropositivity (VISP), where vaccinated individuals test positive despite not having an active infection.
Dipanjan Pan, PhD, a professor of nanomedicine, nuclear engineering, and materials science and engineering at Pennsylvania State University, emphasizes the need for a rapid, affordable, point-of-care test that can separate immune responses caused by vaccination from genuine infection. To tackle laboratory challenges, his team built a device that detects both protein and nucleic acid markers on a single platform.
The device merges electrochemical sensing with machine learning to deliver results in about five minutes. Constructed using a 3D-printed cartridge roughly the size of a smartphone, a drop of blood obtained via lancet passes through four channels. The test simultaneously screens for the HIV p24 protein, anti-p24 antibodies, HIV RNA, and a control RNA molecule.
The key breakthrough lies in including HIV-1 RNA detection, which serves as a definitive sign of active viral replication and is absent in VISP cases. Pan describes this integration as overcoming the main limitation of traditional antibody-based diagnostics.
In a clinical evaluation of 104 samples—encompassing vaccinated and unvaccinated HIV-negative individuals and vaccinated and unvaccinated HIV-positive individuals—the test, aided by AI, produced quantitative results in five minutes and achieved 95% sensitivity and 98% specificity for distinguishing active infection from VISP. The assay also provides an estimate of infection stage (early vs late) based on detected protein antigens and antibodies.
Pan argues that this all-in-one platform represents a major advance in HIV diagnostics by accurately detecting active infection while minimizing VISP-driven false positives. The design’s scalability and relatively low cost make it suitable for broad deployment in both well-resourced and resource-limited settings.
As HIV vaccines gain approval and adoption, VISP could pose challenges for incidence surveillance, outbreak detection, and interpretation of clinical trial data. Relying on standard serological tests could lead to misdiagnoses, causing psychological distress and broader social implications, complicating blood and organ donation, and creating potential hurdles in insurance, employment, travel, immigration, or family planning decisions.
Pan concludes that despite ongoing progress in prevention and treatment, HIV remains a major global health issue. Developing safe, effective vaccines is essential for reducing transmission and ultimately controlling the epidemic. Would this rapid, dual-marker approach become a new standard in HIV testing if widely implemented, or would real-world variability pose new obstacles? Share your thoughts in the comments.
